What is HC Wainwright’s Estimate for Clene FY2024 Earnings?

Clene Inc. (NASDAQ:CLNN) – Research analysts at HC Wainwright lifted their FY2024 earnings per share estimates for Clene in a report released on Wednesday, November 13th. HC Wainwright analyst J. Pantginis now expects that the company will post earnings of ($5.31) per share for the year, up from their previous forecast of ($5.62). HC Wainwright has a “Buy” rating and a $31.00 price target on the stock. The consensus estimate for Clene’s current full-year earnings is ($5.19) per share. HC Wainwright also issued estimates for Clene’s Q4 2024 earnings at ($1.31) EPS, FY2025 earnings at ($5.00) EPS, FY2026 earnings at ($2.77) EPS, FY2027 earnings at $0.75 EPS and FY2028 earnings at $5.53 EPS.

Other equities research analysts also recently issued research reports about the stock. Canaccord Genuity Group decreased their price target on shares of Clene from $86.00 to $83.00 and set a “buy” rating on the stock in a research note on Thursday, November 14th. EF Hutton Acquisition Co. I raised shares of Clene to a “strong-buy” rating in a report on Tuesday, September 10th.

Clene Price Performance

Shares of NASDAQ:CLNN opened at $4.66 on Monday. The firm has a market capitalization of $38.96 million, a PE ratio of -0.88 and a beta of 0.42. The company has a current ratio of 0.83, a quick ratio of 0.82 and a debt-to-equity ratio of 1.66. Clene has a 1-year low of $3.82 and a 1-year high of $12.00. The business’s 50 day moving average is $5.38 and its 200-day moving average is $5.93.

Institutional Trading of Clene

A hedge fund recently bought a new stake in Clene stock. Castleview Partners LLC purchased a new stake in shares of Clene Inc. (NASDAQ:CLNN) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 12,783 shares of the company’s stock, valued at approximately $59,000. Castleview Partners LLC owned approximately 0.19% of Clene at the end of the most recent reporting period. Institutional investors and hedge funds own 23.28% of the company’s stock.

Insider Buying and Selling

In related news, Director David J. Matlin acquired 92,307 shares of the business’s stock in a transaction on Monday, September 30th. The stock was bought at an average cost of $4.75 per share, with a total value of $438,458.25. Following the completion of the acquisition, the director now owns 444,491 shares in the company, valued at $2,111,332.25. The trade was a 26.21 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Mark Mortenson bought 20,512 shares of Clene stock in a transaction dated Monday, September 30th. The stock was purchased at an average price of $4.75 per share, for a total transaction of $97,432.00. Following the purchase, the insider now directly owns 28,949 shares in the company, valued at $137,507.75. This represents a 243.12 % increase in their position. The disclosure for this purchase can be found here. 25.10% of the stock is owned by corporate insiders.

Clene Company Profile

Clene Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.